Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Prostate Cancer

Prostate cancer symptoms: Seven early warning signs from a weak flow to straining

Prostate cancer is the most common cancer in men, and the second most common cancer in the UK, according to National Institute for Health Care and Excellence (NICE). With this in mind, we take a look at seven early warning signs you should never ignore

Daily Mirror

Early telltale prostate cancer signs and symptoms that men should never ignore

One in eight men will suffer from the illness during their lifetime, according to charity figures.

Daily Record

Early symptoms of prostate cancer men need to watch out for

A doctor has explained why and when you should see your GP

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Revolutionary new non-invasive prostate treatment is being rolled out across the UK

A new focal therapy that uses high focused beams of ultrasound or cryotherapy to target and treat the cancer leaving surrounding organs and tissue unharmed is set to offer a new lifeline

Daily Mirror

Fair City's Tommy O'Neill says it's a 'miracle' he's alive after being given months to live

The soap star - who plays Detective John Deegan - was told he had prostate cancer in 2020 and told he would be lucky to survive another 18 months

Dublin Live

New prostate cancer treatment using ultrasound rolling out across UK

One in eight men will be diagnosed with prostate cancer in their lifetime

The Independent UK

Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) and Accord Healthcare Ltd have entered into an exclusive license agreement to commercialize Orgovyx (relugolix) for advanced hormone-sensitive prostate cancer in the European Economic Area, the U.K., Switzerland, and Turkey. Accord has the right to the first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Revolutionary new non-invasive prostate treatment is being rolled out across the UK

A new focal therapy that uses high focused beams of ultrasound or cryotherapy to target and treat the cancer leaving surrounding organs and tissue unharmed is set to offer a new lifeline

Wales Online

Male weight loss could slash prostate cancer deaths according to new study

Findings show that prostate cancer deaths could reduce significantly if less men were overweight

Daily Record

Lowndes to race prostate cancer Porsche at Bathurst

Craig Lowndes will spearhead the driver line-up for a Porsche that will promote the Prostate Cancer Foundation of Australia at the Bathurst 12 Hour.

Motorsport

1,300 prostate cancer deaths could be prevented if men lose weight - study

Experts are starting to unpick the link between prostate cancer and weight

Wales Online

1,300 prostate cancer deaths could be prevented if men lose weight – study

Having a higher BMI and a larger waistline has been linked to a higher risk of death from prostate cancer.

The Independent UK

Bryce Miller: How and why Steve Lavin wound up coaching basketball in San Diego

SAN DIEGO — In a horseshoe-shaped booth at bustling Manhattan of La Jolla, Steve Lavin used the better part of 3 1/2 hours to explore the people who have influenced his life, being a 32-year-old college basketball coach under the withering spotlight at UCLA, the prostate cancer that reconfigured perspective…

Tribune News Service

Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer. This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…

Daily Mirror

Drug to help millions suffering 'urge to pee' could soon be available in UK

Overactive bladder (OAB) silently impacts the lives of countless women in the UK by causing an uncontrollable and distressing urge to urinate during the day and through the night

Benzinga

QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics…

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT

Asharq Al-Awsat

Discovery of Prostate Cancer Linked-Bacteria Could Pave Way for Treatment

Scientists have discovered bacteria linked to aggressive prostate cancer in work hailed as a potential revolution for the prevention and treatment of the disease, reported The Guardian. Researchers led by the University of East Anglia performed sophisticated genetic analyses on the urine and prostate tissue of more than 600 men…

Get all your
news in one place.

100’s of premium titles.
One news app.

1 … 29 30 31 32

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.